HIV/AIDS
Studies from B. Hoen and co-authors have provided new information about HIV/AIDS
Published in AIDS Weekly, October 8th, 2007
According to recent research from London, the United Kingdom, "Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome, virological and immunological changes, and adverse events were evaluated over 48 weeks. One hundred forty-eight patients started antiretroviral therapy during primary HIV-1 infection with <= 3 bands on Western Blot ( median plasma HIV-1 RNA load, 5.4 log copies/mL; median CD4 cell count, 517 cells/mm(3))."
"By week 48, 36% of patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-10-08)
More Articles from AIDS Weekly
- Bioterrorism
SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors - HIV/AIDS
AHF Launches 'Public Health Division' - HIV/AIDS
AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy - HIV/AIDS
Cytheris Expands Interleukin-7 Clinical Development Program With International Phase I/IIa Trial In HIV - HIV/AIDS
GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial - HIV/AIDS
Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
